FOR IMMEDIATE RELEASE
LABOPHARM ANNOUNCES COMPLETION OF
JOINT VENTURE WITH ANGELINI
Laval, Québec (May 20, 2010) - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it
has completed the previously announced transaction to establish a joint venture with Gruppo Angelini. The joint
venture, Angelini Labopharm, will launch OLEPTRO™, Labopharm’s novel once-daily formulation of trazodone
indicated for the treatment of major depressive disorder in adults, in the U.S. in the third quarter of this year.
Terms of the joint venture agreement will be available in Labopharm’s related regulatory filings with SEDAR and
About Labopharm Inc.
Headquartered in Laval, Canada with US offices in Princeton, New Jersey, Labopharm is an emerging leader in
optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies.
The Company's lead product, a unique once-daily formulation of tramadol, is now available in 19 countries
around the world, including the U.S., Canada, major European markets, South Korea and Australia. Its second
product, OLEPTRO™, a novel formulation of trazodone for the treatment of major depressive disorder in adults,
has received regulatory approval in the U.S. and is under regulatory review in Canada. Labopharm has initiated
the European regulatory approval process for its third product, a twice-daily formulation of tramadol-
acetaminophen. The Company also has a pipeline of follow-on products in both pre-clinical and clinical
This press release contains forward-looking statements, including statements concerning the ability of the joint venture to timely launch and
market OLEPTRO™ in the United States, which reflect the Company's current expectations regarding future events. These forward-looking
statements involve risks and uncertainties, many of which are beyond the Company’s control. Actual events could differ materially from those
projected herein and